Clopidogrel: still king of the ring for elective percutaneous coronary intervention!

EuroIntervention 2023;18:1213-1214. DOI: 10.4244/EIJ-E-23-00003

Gilles Montalescot
Gilles Montalescot1, MD, PhD; Arnaud Ferrante1, MD
1. ACTION Study Group, Sorbonne Université, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
Clopidogrel is the P2Y12 inhibitor of choice for elective percutaneous coronary intervention (PCI) and is recommended in the current guidelines for the management of chronic coronary syndrome (CCS)1. Post-PCI elevation of cardiac biomarkers related to cardiac myonecrosis remains, however, a common complication particularly with the wider use of high-sensitivity cardiac troponin2. Such complications affect patients’ prognoses, including all-cause mortality and major cardiovascular events, notably in cases of major periprocedural myocardial infarction (MI) or type 4a MI3. Consequently, strategies have been considered to prevent these complications, including the off-label use of more potent P2Y12 inhibitors. Prasugrel and ticagrelor ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Effects of PCSK9 inhibitors on platelet function

Latest news